PFE · Pfizer, Inc.
Is PFE setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Pfizer, Inc., in one place.
Today's breakout radarIs PFE setting up for a breakout?
Breakout Radar API →PFE reports earnings on Nov 3, 2026 — a breakout right before a report can reverse on the numbers.
Not today. PFE is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about PFE?
Stock Sentiment API →Bulls: FDA expanded approval of TALZENNA plus XTANDI into earlier-line metastatic prostate cancer (announced October 26, 2026) for hormone-sensitive patients; in a 599-patient Phase 3 trial the combo cut the risk of radiographic progression or death by 52%, though overall-survival data remain immature. ELREXFIO met the primary endpoint in the Phase 3 MagnetisMM-32 trial in relapsed/refractory multiple myeloma, outperforming standard regimens in an earlier treatment line (reported October 27, 2026), strengthening the case for downstream regulatory activity. A new children's pneumonia vaccine covering up to 25 strains showed strong immunity across all strains in Phase 2, with large-scale trials planned to replace Prevnar 20. Technically, the stock broke out to a 52-week high (filled 29.92, closed 30.03), with a breakout above 30.50 cited as opening 'big blue skies,' and one trader trimmed 25% into strength.
Bears: Vyndamax family grew just 8% operationally in Q2, with Pfizer blaming net price erosion from new US payer contracts — slow growth that is worrying for PFE given Vyndamax was 10% of 2025 earnings. Critics note Pfizer hardly ever comes up in pipeline-drug competitive landscaping, and that its Vyndaqel-family spending (~$839k on consulting, 5.9× relative 2024) outpaced all competitor assets despite an inferior drug. One comparison flags Pfizer's trispecific TSLP × IL-4 × IL-13 Tilrekimig as more advanced than ACRS's ATI-052, and skeptics argue a similar cancer breakthrough at PFE would have dumped 10% rather than pumping.
Reading from Oct 27, 2026; each post classified by AI, weighted by engagement.
What is the news saying about PFE?
News Sentiment API →No recent news reading for PFE. The News Sentiment API reads today's headlines on any US stock.
Are PFE insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Bought · BOURLA ALBERT$1.0M · Aug 12, 2026
- Sold · DAMICO JENNIFER B.$83K · Aug 5, 2026
- Bought · BLAYLOCK RONALD E$999K · Aug 5, 2026
- Bought · Buckley Mortimer J$960K · Aug 5, 2026
- Sold · DAMICO JENNIFER B.$51K · Jun 9, 2026
How is Pfizer, Inc.'s business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 28, 2026 | $15.0B | +3% | −$248.0M | $-0.04 |
| Mar 29, 2026 | $14.5B | +5% | $2.7B | $0.47 |
| Sep 28, 2025 | $16.7B | -6% | $3.5B | $0.62 |
| Jun 29, 2025 | $14.7B | +10% | $2.9B | $0.51 |
From the company's SEC filings (10-Q and 10-K).
What does Pfizer, Inc. expect?
Company Guidance API →- Full-Year 2025 · revenue · 8-K filed Dec 16, 2025
“Reaffirms Full-Year 2025 Adjusted (1) Diluted EPS Guidance (2) and Revises Full-Year 2025 Revenue Guidance (2) to Approximately $62.0 Billion”
- Full-Year 2026 · revenue · 8-K filed Dec 16, 2025
“Full-Year 2026 Revenue Guidance (2) Range of $59.5 to $62.5 Billion”
- Full-Year 2026 · adjusted diluted eps · 8-K filed Dec 16, 2025
“Full-Year 2026 Adjusted (1) Diluted EPS Guidance (2) Range of $2.80 to $3.00”
- Full-Year 2026 · adjusted si&a expenses · 8-K filed Dec 16, 2025
“Pfizer anticipates full-year 2026 Adjusted (1) SI&A expenses to be in the range of $12.5 to $13.5 billion”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.